Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $3.8 million.

  • Lineage Cell Therapeutics' Current Deferred Revenue fell 5435.15% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year decrease of 5435.15%. This contributed to the annual value of $7.4 million for FY2024, which is 3164.32% down from last year.
  • Lineage Cell Therapeutics' Current Deferred Revenue amounted to $3.8 million in Q3 2025, which was down 5435.15% from $5.3 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Current Deferred Revenue ranged from a high of $50.5 million in Q4 2021 and a low of $101000.0 during Q1 2021
  • Its 5-year average for Current Deferred Revenue is $18.3 million, with a median of $9.4 million in 2022.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 9788.04% in 2021, then soared by 4504851.49% in 2022.
  • Lineage Cell Therapeutics' Current Deferred Revenue (Quarter) stood at $50.5 million in 2021, then tumbled by 81.34% to $9.4 million in 2022, then increased by 14.72% to $10.8 million in 2023, then tumbled by 31.64% to $7.4 million in 2024, then crashed by 49.03% to $3.8 million in 2025.
  • Its Current Deferred Revenue stands at $3.8 million for Q3 2025, versus $5.3 million for Q2 2025 and $6.9 million for Q1 2025.